Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy
Imaging plays a pivotal role in the diagnostic and prognostic assessment of cardiovascular diseases. During the past two decades, there has been an expansion of the available imaging techniques, some of which are now part of routine clinical practice. Cardiovascular imaging of atherosclerosis is a u...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2019-01-01
|
| Series: | European Cardiology Review |
| Online Access: | https://www.ecrjournal.com/articles/cardiovascular-imaging-and-theranostics-cardiovascular-pharmacotherapy |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850104681788866560 |
|---|---|
| author | Mattia Cattaneo Alberto Froio Augusto Gallino |
| author_facet | Mattia Cattaneo Alberto Froio Augusto Gallino |
| author_sort | Mattia Cattaneo |
| collection | DOAJ |
| description | Imaging plays a pivotal role in the diagnostic and prognostic assessment of cardiovascular diseases. During the past two decades, there has been an expansion of the available imaging techniques, some of which are now part of routine clinical practice. Cardiovascular imaging of atherosclerosis is a useful instrument, and it can corroborate and expand pathophysiological evidence on cardiovascular disease, providing proof of concept for medical therapy and can predict its responsiveness, and it may be able to be used as surrogate endpoints for clinical trials. Theranostics is an emerging therapy that combines imaging and therapeutic functions, using imaging-based therapeutic delivery systems. Theranostics could partially overcome current imaging limitations and translate experimental evidence and large-scale trials assessing clinical endpoints, rationalising cardiovascular drug development and paving the way to personalised medicine. The medical community cannot overlook the use of cardiovascular imaging as a complementary and supportive adjunct to trials investigating clinical endpoints, which remain the mainstay for investigating the efficacy and safety of cardiovascular pharmacotherapy. |
| format | Article |
| id | doaj-art-05ae3bd5e640416c8fbc9c9c1e3ada32 |
| institution | DOAJ |
| issn | 1758-3756 1758-3764 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | European Cardiology Review |
| spelling | doaj-art-05ae3bd5e640416c8fbc9c9c1e3ada322025-08-20T02:39:16ZengRadcliffe Medical MediaEuropean Cardiology Review1758-37561758-37642019-01-01141626410.15420/ecr.2019.6.1Cardiovascular Imaging and Theranostics in Cardiovascular PharmacotherapyMattia Cattaneo0Alberto Froio1Augusto Gallino2Cardiovascular Research Unit, Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland; Department of Cardiovascular Intensive Care, Cardiocentro Ticino, Lugano, SwitzerlandDepartment of Surgery and Interdisciplinary Medicine, University of Milano-Bicocca, Milan, ItalyCardiovascular Research Unit, Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland;Imaging plays a pivotal role in the diagnostic and prognostic assessment of cardiovascular diseases. During the past two decades, there has been an expansion of the available imaging techniques, some of which are now part of routine clinical practice. Cardiovascular imaging of atherosclerosis is a useful instrument, and it can corroborate and expand pathophysiological evidence on cardiovascular disease, providing proof of concept for medical therapy and can predict its responsiveness, and it may be able to be used as surrogate endpoints for clinical trials. Theranostics is an emerging therapy that combines imaging and therapeutic functions, using imaging-based therapeutic delivery systems. Theranostics could partially overcome current imaging limitations and translate experimental evidence and large-scale trials assessing clinical endpoints, rationalising cardiovascular drug development and paving the way to personalised medicine. The medical community cannot overlook the use of cardiovascular imaging as a complementary and supportive adjunct to trials investigating clinical endpoints, which remain the mainstay for investigating the efficacy and safety of cardiovascular pharmacotherapy.https://www.ecrjournal.com/articles/cardiovascular-imaging-and-theranostics-cardiovascular-pharmacotherapy |
| spellingShingle | Mattia Cattaneo Alberto Froio Augusto Gallino Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy European Cardiology Review |
| title | Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy |
| title_full | Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy |
| title_fullStr | Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy |
| title_full_unstemmed | Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy |
| title_short | Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy |
| title_sort | cardiovascular imaging and theranostics in cardiovascular pharmacotherapy |
| url | https://www.ecrjournal.com/articles/cardiovascular-imaging-and-theranostics-cardiovascular-pharmacotherapy |
| work_keys_str_mv | AT mattiacattaneo cardiovascularimagingandtheranosticsincardiovascularpharmacotherapy AT albertofroio cardiovascularimagingandtheranosticsincardiovascularpharmacotherapy AT augustogallino cardiovascularimagingandtheranosticsincardiovascularpharmacotherapy |